When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition

Journal of Investigative Dermatology

Volumn 131, Issue 11, 2011, Pages 2169-2173

  Furio, Laetitia ^a,b   Hovnanian, Alain ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN 1; KALLIKREIN 5; LYMPHOEPITHELIAL KAZAL TYPE RELATED INHIBITOR; PROTEINASE INHIBITOR; SERINE PROTEINASE; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NETHERTON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SKIN EXFOLIATION; STRUCTURE ANALYSIS;

EID: 80054743877     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.295     Document Type: Note

References (34)

1. Ahmed A, Kandola P, Ziada G et al. (2001) Purification and partial amino acid sequence of proteins from human epidermal keratinocyte conditioned medium. J Protein Chem 20:273-8
2. Bitoun E, Chavanas S, Irvine A et al. (2002) Netherton syndrome: Disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol 118:352-61 (Pubitemid 34158493)
3. Bitoun E, Micheloni A, Lamant L et al. (2003) LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet 12:2417-30 (Pubitemid 37220407)
4. Bonnart C, Deraison C, Lacroix M et al. (2010) Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest 120:871-82
5. Borgoño CA, Michael IP, Komatsu N et al. (2007) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 282:3640-52 (Pubitemid 47084449)
6. Brattsand M, Stefansson K, Lundh C et al. (2005) A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 124:198-203 (Pubitemid 40100969)
7. Brattsand M, Stefansson K, Hubiche T et al. (2009) SPINK9: A selective, skin-specific Kazal-type serine protease inhibitor. J Invest Dermatol 129:1656-65
8. Briot A, Deraison C, Lacroix M et al. (2009) Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 206:1135-47
9. Briot A, Lacroix M, Robin A et al. (2010) Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol 130:2736-42
10. Chavanas S, Bodemer C, Rochat A et al. (2000) Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 25:141-2 (Pubitemid 30394980)
11. Deraison C, Bonnart C, Lopez F et al. (2007) LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 18:3607-19 (Pubitemid 47378698)
12. Descargues P, Deraison C, Bonnart C et al. (2005) Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 37:56-65 (Pubitemid 40070940)
13. Descargues P, Deraison C, Prost C et al. (2006) Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol 126:1622-32
14. Egelrud T, Brattsand M, Kreutzmann P et al. (2005) hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br J Dermatol 153:1200-3 (Pubitemid 41779577)
15. Fontao L, Laffitte E, Briot A et al. (2011) Infliximab infusions for Netherton syndrome: Sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol 131:1947-50
16. Fortugno P, Bresciani A, Paolini C et al. (2011) Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: Implications for skin homeostasis. J Invest Dermatol 131:2223-32
17. Goettig P, Magdolen V, Brandstetter H (2010) Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 92:1546-67
18. Hachem JP, Houben E, Crumrine D et al. (2006) Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 126:2074-86
19. Hewett DR, Simons AL, Mangan NE et al. (2005) Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Hum Mol Genet 14:335-46
20. Ishida-Yamamoto A, Deraison C et al. (2005) LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol 124:360-6 (Pubitemid 40175883)
21. Jayakumar A, Kang Y, Mitsudo K et al. (2004) Expression of LEKTI domains 6-9' in the baculovirus expression system: Recombinant LEKTI domains 6-9' inhibit trypsin and subtilisin A. Protein Expr Purif 35:93-101 (Pubitemid 38497911)
22. Komatsu N, Saijoh K, Toyama T et al. (2005) Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br J Dermatol 153:274-81 (Pubitemid 41228422)
23. Kreutzmann P, Schulz A, Standker L et al. (2004) Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: A temporary Kazal-type-related serine proteinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci 803:75-81 (Pubitemid 38340640)
24. Magert HJ, Standker L, Kreutzmann P et al. (1999) LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 274:21499-502
25. Magert HJ, Drogemuller K, Raghunath M (2005) Serine proteinase inhibitors in the skin: Role in homeostasis and disease. Curr Protein Pept Sci 6:241-54 (Pubitemid 40812748)
26. Meyer-Hoffert U (2009) Reddish, scaly, and itchy: How proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz) 57:345-54
27. Meyer-Hoffert U, Wu Z, Kantyka T et al. (2010) Isolation of SPINK6 in human skin: Selective inhibitor of kallikrein-related peptidases. J Biol Chem 285:32174-81
28. Mitsudo K, Jayakumar A, Henderson Y et al. (2003) Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: A kinetic analysis. Biochemistry 42:3874-81 (Pubitemid 36402680)
29. Ovaere P, Lippens S, Vandenabeele P (2009) The emerging roles of serine protease cascades in the epidermis. Trends Biochem Sci 34:453-63
30. Schechter NM, Choi EJ, Wang ZM et al. (2005) Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem 386:1173-84 (Pubitemid 41705372)
31. Tartaglia-Polcini A, Bonnart C, Micheloni A et al. (2006) SPINK5, the defective gene in Netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing. J Invest Dermatol 126:315-24 (Pubitemid 43323166)
32. Walley AJ, Chavanas S, Moffatt MF et al. (2001) Gene polymorphism in Netherton and common atopic disease. Nat Genet 29:175-8 (Pubitemid 32952654)
33. Yang T, Liang D, Koch PJ et al. (2004) Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosin in Spink5-/- mice. Genes Dev 18:2354-8 (Pubitemid 39304682)
34. Zeeuwen PL (2004) Epidermal differentiation: The role of proteases and their inhibitors. Eur J Cell Biol 83:761-3